Figure 4.

Treatment with 17V05 potently inhibited the production of multiple proinflammatory cytokines and chemokines by RPE cells. (a) Treatment with 17V05 inhibited the secretion of IL-6 from RPE cells as effectively as 608, whereas bevacizumab had no effects (n = 3). (b) Treatment with 17V05 inhibited the secretion of IL-8 from RPE cells as effectively as 608, whereas bevacizumab had no effects (n = 3). (c) The 17V05 protein inhibited the secretion of CXCL1 from RPE cells as effectively as 608, whereas bevacizumab had no effects (n = 3). (d) The 17V05 protein inhibited the secretion of MCP-1 from RPE cells as effectively as 608, whereas bevacizumab had no effects (n = 3). All assays were performed in triplicate. IL-6: interleukin-6, IL-8: interleukin-8, CXCL1: the chemokine (C-X-C motif) ligand-1, and MCP-1: monocyte chemoattractant protein-1.